Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.57 |
| ▸ | CTSK | P43235 | 5/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16774 | 1.00 | CTSS (0.57) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL16119327 | 0.92 | CTSS (0.52) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL26120706 | 0.92 | CTSS (0.52) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL956167 | 0.90 | CTSS (0.68) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL956164 | 0.90 | CTSS (0.68) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL1351322 | 0.90 | CTSS (0.68) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL2199576 | 0.88 | CTSK (0.53) | CTSSCTSKAAK1KMT2ACTSL | |
| SCHEMBL2199572 | 0.88 | CTSK (0.53) | CTSSCTSKAAK1KMT2ACTSL | |
| SCHEMBL16800 | 0.88 | CTSK (0.53) | CTSSCTSKAAK1KMT2ACTSL | |
| SCHEMBL24298421 | 0.87 | CTSK (0.64) | CTSSCTSKIDO1AAK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-117836270-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-109563033-B | Aliphatic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022192562-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008116107-A2 | PIPERAZINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | HTRA1, ALDH1A2, PREP | CTSS 746/4885CTSK 1449/4885IDO1 170/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | CTSS 3694/4885CTSK 851/4885IDO1 3779/4885 |
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CTSS 1158/4885CTSK 1629/4885IDO1 233/4885 |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | CTSS 2213/4885CTSK 2165/4885IDO1 3220/4885 |
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CTSS 843/4885CTSK 100/4885IDO1 4551/4885 |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CTSS 843/4885CTSK 100/4885IDO1 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.